ArticleRSC advances2026
A human serum albumin-assisted caged fluorophore probe for fluorescence turn-on detection of hypochlorous acid.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fluorescence detection of hypochlorous acid (HOCl), a reactive oxidant that modulates immune responses and inflammation, can be complicated in serum due to nonspecific interactions between fluorescent probes and serum proteins. In particular, human serum albumin (HSA), the most abundant protein in serum, can alter the probe fluorescence by increasing background signals and distorting analyte-dependent responses. Rather than suppressing this protein-induced effect, we sought to convert albumin binding into a controlled signal-generation step. Here, we report DSH, an HSA-assisted caged fluorophore probe for HOCl detection in albumin-containing media. DSH was constructed by masking dansyl-sarcosine (DS) with a 2,4-dinitrophenyl caging group through a hydrazine-based linker that undergoes oxidative cleavage in response to HOCl. In the caged state, fluorescence is suppressed, and direct albumin-induced activation is minimised. Upon exposure to HOCl, oxidative cleavage of the linker releases DS, which subsequently binds to HSA and produces a fluorescence turn-on response. Thus, HSA binding, typically considered a source of matrix interference, is repurposed as a signal-amplifying step in the sensing mechanism. This DSH-based sensing strategy enables calibration-based quantitative detection of HOCl in phosphate-buffered saline supplemented with HSA and diluted human serum, supporting the feasibility of this caged-fluorophore design under controlled albumin-containing conditions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.